Amgen, Inc. has set the bar for Humira (adalimumab) biosimilar launches in the US with the 31 January launch of Amjevita, the first adalimumab biosimilar to enter the market, but with two different prices – at a 55% and 5% discount to AbbVie Inc.’s pricing for the originator product.
The strategy gives payers two options from which to start reimbursement negotiations, highlighting one of the key challenges biosimilar manufacturers...




